HALO
Halozyme Therapeutics Inc
110.80$
+1.0%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 25.4% | 22.7% | 23.5% | 24.8% | 17.0% | 14.1% | 25.0% | 19.7% | 15.6% | 17.4% | 21.0% | 16.5% | 17.6% | |
| 74.6% | 77.3% | 76.5% | 75.2% | 83.0% | 85.9% | 75.0% | 80.3% | 84.4% | 82.6% | 79.0% | 83.5% | 82.4% | |
| 8.0% | 9.3% | 9.8% | 9.1% | 6.4% | 6.9% | 5.6% | 5.4% | 4.9% | 7.1% | 6.8% | 5.8% | 6.2% | |
| 16.3% | 16.3% | 17.9% | 15.4% | 14.2% | 14.2% | 16.0% | 12.8% | 13.0% | 17.1% | 15.4% | 11.8% | 14.3% | |
| 33.8% | 33.3% | 27.7% | 24.5% | 26.7% | 27.0% | 21.6% | 18.2% | 22.9% | 29.3% | 30.0% | 23.7% | 26.5% | |
| 40.9% | 43.9% | 48.8% | 50.7% | 56.3% | 58.9% | 53.4% | 62.2% | 61.5% | 53.3% | 49.0% | 59.8% | 55.9% | |
| 2.1% | 2.3% | 2.3% | 2.0% | 1.6% | 1.5% | 1.7% | 1.3% | 1.2% | 1.1% | 1.5% | 1.2% | 1.2% | |
| 47.1% | 44.0% | 49.0% | 50.9% | 56.9% | 59.8% | 54.3% | 62.9% | 61.8% | -22.3% | 47.9% | 59.2% | 35.1% | |
| 9.2% | 6.9% | 9.8% | 10.6% | 9.7% | 13.8% | 9.7% | 12.2% | 12.3% | 9.0% | 8.0% | 11.4% | 10.2% | |
| 37.9% | 37.1% | 39.2% | 40.3% | 47.2% | 46.0% | 44.6% | 50.7% | 49.5% | -31.3% | 39.8% | 47.8% | 24.9% | |
| 59.9% | 55.2% | 61.6% | 61.6% | 65.5% | 68.2% | 63.7% | 70.5% | 68.8% | -15.3% | 58.3% | 67.5% | 43.2% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.